Prediction of combination therapies based on topological modeling of the immune signaling network in Multiple Sclerosis
Dimitris E Messinis,
Janina R Behrens,
Leonidas G Alexopoulos,
Posted 05 Feb 2019
bioRxiv DOI: 10.1101/541458
Posted 05 Feb 2019
Signal transduction deregulation is a hallmark of many complex diseases, including Multiple Sclerosis (MS). Here, we performed ex vivo multiplexed phosphoproteomic assays upon perturbations with multiple drugs and ligands in primary immune cells from 169 MS patients and matched healthy controls. Patients were either untreated or treated with fingolimod, natalizumab, interferon-β, glatiramer acetate or the experimental therapy epigallocatechin gallate (EGCG). We generated for each donor a dynamic logic model by fitting a bespoke literature-derived network of MS-related pathways to the perturbation data. Analysis of the models uncovered features of healthy-, disease- and drug-specific signaling networks. We developed an approach based on network topology to identify deregulated interactions whose activity could be reverted to a "healthy-like" status by combination therapy. We predicted several combinations with approved MS drugs. Specifically, TAK1 kinase, involved in TGF-β, Toll-like receptor, B-cell receptor and response to inflammation pathways were found to be highly deregulated and co-druggable with all MS drugs studied. One of these predicted combinations, fingolimod with a TAK1 inhibitor, was validated in an animal model of MS. Our approach based on donor-specific signaling networks enables prediction of targets for combination therapy for MS and other complex diseases.
- Downloaded 798 times
- Download rankings, all-time:
- Site-wide: 15,340 out of 85,018
- In systems biology: 432 out of 2,238
- Year to date:
- Site-wide: 28,702 out of 85,018
- Since beginning of last month:
- Site-wide: 14,351 out of 85,018
Downloads over time
Distribution of downloads per paper, site-wide
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!